Patent Holder
Benjamin Faustin
• US patent from the National Institute of Health regarding the discovery and design of peptides derived from
Bcl-2 and the viral Bcl-2 homolog protein F1L originally encoded by vaccinia viruses. These peptides mediate the
inhibition of NALP1 inflammasome, and thus have therapeutic potential to treat inflammatory diseases such as Vitiligo,
Crohn’s disease, Arthritis. « COMPOSITIONS AND METHODS FOR MODULATING NOD-LIKE RECEPTOR
ACTIVITY AND USES THEREOF » (1) United States Application filed on July 16, 2009 and assigned Application
No. 12/504,649 and (2) an International Patent Application filed on July 16, 2009 and assigned Application No.
PCT/US09/50907; The Burnham Institute for Medical Research, La Jolla, CA.
Bcl-2 and the viral Bcl-2 homolog protein F1L originally encoded by vaccinia viruses. These peptides mediate the
inhibition of NALP1 inflammasome, and thus have therapeutic potential to treat inflammatory diseases such as Vitiligo,
Crohn’s disease, Arthritis. « COMPOSITIONS AND METHODS FOR MODULATING NOD-LIKE RECEPTOR
ACTIVITY AND USES THEREOF » (1) United States Application filed on July 16, 2009 and assigned Application
No. 12/504,649 and (2) an International Patent Application filed on July 16, 2009 and assigned Application No.
PCT/US09/50907; The Burnham Institute for Medical Research, La Jolla, CA.